NKTX Live signals | Maximize Profits with Getagraph.com

BUY 94420 min ago

@ $10.55

Issued: 14 Feb 2024 @ 10:41

Return: -30.87%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -3.61 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	730 386
Average Volume	1.01M
Market Cap	513.71M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.550 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.04
ATR14	$0.0130 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Ra Capital Management, L.p.	Buy	3 000 000	Common Stock
2024-03-27	Ra Capital Management, L.p.	Buy	3 000 031	Pre- Funded Warrants (Right to Buy)
2024-03-27	George Simeon	Buy	1 548 341	Common Stock
2024-03-27	George Simeon	Buy	451 659	Common Stock
2024-03-01	Hastings Paul J	Sell	12 358	Common Stock

INSIDER POWER
95.69
Last 99 transactions
Buy: 11 537 422 \| Sell: 349 926

Volume Correlation

Long: 0.23 (neutral)

Short: 0.09 (neutral)

Signal:(46.744) Neutral

Nkarta, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nkarta, Inc. Correlation - Currency/Commodity

0.17
( neutral )

-0.30
( neutral )

0.00
( neutral )

-0.71
( moderate negative )

0.62
( weak )

Nkarta, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-5.87M (0.00 %)
EPS:	$-2.40

Q4	2023
Revenue:	$0
Gross Profit:	$-2.25M (0.00 %)
EPS:	$-0.570

Q3	2023
Revenue:	$0
Gross Profit:	$-2.54M (0.00 %)
EPS:	$-0.520

Q2	2023
Revenue:	$0
Gross Profit:	$-1.39M (0.00 %)
EPS:	$-0.680

Financial Reports:

No articles found.

Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.